Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | HPGD | P15428 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27599862 | 0.79 | HSD11B1 (0.38) | KDM4EL3MBTL1TDP1HSD11B1 | |
| SCHEMBL4089117 | 0.79 | PRMT5 (0.50) | ALDH1A1HPGDMAPTKDM4EL3MBTL1 | |
| SCHEMBL27618397 | 0.77 | HTR1A (0.37) | KMT2AMEN1 | |
| SCHEMBL150626 | 0.77 | HSD11B1 (0.38) | GAAHPGDMAPTKMT2ANPSR1 | |
| SCHEMBL149845 | 0.77 | ALDH1A1 (0.38) | GAAALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL29151406 | 0.77 | ALDH1A1 (0.45) | GAAALDH1A1HPGDMAPTKDM4E | |
| SCHEMBL4075611 | 0.76 | ALDH1A1 (0.53) | GAAALDH1A1HPGDMAPTKDM4E | |
| SCHEMBL2905044 | 0.76 | SMN1; SMN2 (0.38) | GAAALDH1A1HPGDMAPTKDM4E | |
| SCHEMBL2083022 | 0.75 | PKM (0.51) | GAAALDH1A1HPGDMAPTKDM4E | |
| SCHEMBL3000425 | 0.74 | NLRP3 (0.43) | ALDH1A1MAPTKDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534808-B2 | Indolylmaleimide derivatives | ELANCO TIERGESUNDHEIT AG (CH) | 2009-05-19 | — | — | US | disclosed |
| US-7534808-B2 | Indolylmaleimide derivatives | ELANCO TIERGESUNDHEIT AG (CH) | 2009-05-19 | — | — | US | disclosed |
| US-7534808-B2 | Indolylmaleimide derivatives | ELANCO TIERGESUNDHEIT AG (CH) | 2009-05-19 | — | — | US | disclosed |
| US-20080146578-A1 | INDOLYLMALEIMIDE DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2008-06-19 | — | — | US | disclosed |
| US-20080146578-A1 | INDOLYLMALEIMIDE DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2008-06-19 | — | — | US | disclosed |
| US-20080146578-A1 | INDOLYLMALEIMIDE DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2008-06-19 | — | — | US | disclosed |
| US-20080108628-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC; may be coadminstered with an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug | EVENOU JEAN-PIERRE | 2008-05-08 | — | — | US | disclosed |
| US-20080108628-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC; may be coadminstered with an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug | EVENOU JEAN-PIERRE | 2008-05-08 | — | — | US | disclosed |
| US-20080108628-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC; may be coadminstered with an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug | EVENOU JEAN-PIERRE | 2008-05-08 | — | — | US | disclosed |
| US-7358253-B2 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2008-04-15 | — | — | US | disclosed |
| US-7235555-B2 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2007-06-26 | — | — | US | disclosed |
| US-20070037826-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC, e.g., acute or chronic rejection of organ or tissue allo- or xenografts or graft versus host disease | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-15 | — | — | US | disclosed |
| US-20070037826-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC, e.g., acute or chronic rejection of organ or tissue allo- or xenografts or graft versus host disease | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-15 | — | — | US | disclosed |
| US-20070037826-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC, e.g., acute or chronic rejection of organ or tissue allo- or xenografts or graft versus host disease | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-15 | — | — | US | disclosed |
| US-20070032507-A1 | Indolylmaleimide derivatives | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-08 | — | — | US | disclosed |
| US-20070032507-A1 | Indolylmaleimide derivatives | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-08 | — | — | US | disclosed |
| US-20070032507-A1 | Indolylmaleimide derivatives | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-08 | — | — | US | disclosed |
| US-20050119274-A1 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2005-06-02 | — | — | US | disclosed |
| EP-1490355-A1 | INDOLYLMALEIMIDE DERIVATIVES | Novartis AG (CH) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003082859-A1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032507-A1 | Indolylmaleimide derivatives | MYLK2, DGKK, LCK | GAA 4153/4885ALDH1A1 3744/4885HPGD 2531/4885 |
| US-20080108628-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC; may be coadminstered with an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug | NFATC1, CD4, LCK | GAA 1456/4885ALDH1A1 3642/4885HPGD 1305/4885 |
| US-20050119274-A1 | Indolylmaleimide derivatives | MYLK2, DGKK, LCK | GAA 4153/4885ALDH1A1 3744/4885HPGD 2531/4885 |
| US-20080146578-A1 | INDOLYLMALEIMIDE DERIVATIVES | MYLK2, LCK, DGKK | GAA 4257/4885ALDH1A1 3764/4885HPGD 2728/4885 |
| US-20070037826-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC, e.g., acute or chronic rejection of organ or tissue allo- or xenografts or graft versus host disease | DGKK, DGKG, HLA-DRB1 | GAA 3308/4885ALDH1A1 4089/4885HPGD 3619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.